CERo Therapeutics (CERO) said Tuesday that the US Food and Drug Administration has granted orphan drug designation for its lead drug candidate, CER-1236, for acute myeloid leukemia.
Shares jumped over 220% as intraday trading volume advanced to over 51.2 million from a daily average of about 101,000.
Acurx Pharmaceuticals (ACXP) said its lead antibiotic candidate, ibezapolstat, is ready to advance to international phase 3 clinical trials to treat patients with C. difficile infection.
Shares soared over 130% as intraday trading volume surged to more than 309 million from a daily average of roughly 182,000.
Eli Lilly (LLY) said that it agreed to acquire Verve Therapeutics (VERV) for up to about $1.3 billion to advance gene-editing therapies for cardiovascular disease.
Verve shares soared 78%, with intraday trading volume of more than 72.5 million against a daily average of about 3.49 million.
Price: 22.04, Change: +15.18, Percent Change: +220.97
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。